Trial Profile
A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Amcasertib (Primary) ; Napabucasin (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America; Sumitomo Pharma Oncology
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 30 Sep 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.
- 25 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2019.